Cargando...
Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents
One impediment to the use of TRAIL receptor targeted agents as anti-tumor drugs is the evolution of resistance, a common problem in cancer. On the other hand, many different kinds of drugs synergize with TRAIL in TRAIL-sensitive tumor cells, raising the question whether one can overcome resistance w...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2011
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3250348/ https://ncbi.nlm.nih.gov/pubmed/21363923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-2252 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|